Jiang Huishan, Tian Bo, Gao Ye, Bian Yan, Yu Chuting, Xu Jinfang, Wang Wei, Lin Han, Xin Lei, Wang Luowei
Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, China; National Clinical Research Center for Digestive Diseases (Shanghai), Shanghai, China.
Department of Health Statistics, Naval Medical University, Shanghai, China.
Gastrointest Endosc. 2024 Dec;100(6):1006-1019.e10. doi: 10.1016/j.gie.2024.07.013. Epub 2024 Jul 22.
The risk and pathologic factors of recurrence after endoscopic resection (ER) for superficial esophageal squamous cell carcinoma (ESCC) are inconsistent across studies. We evaluated this in a systematic review and meta-analysis.
The data of recurrence in such patients were extracted from all studies. Risk ratios (RRs) were combined using random-effects meta-analysis to assess pooled recurrence rate and pathologic risk factors. Relapse-free survival was combined using the Kaplan-Meier method to estimate the relationship between various pathologic factors and recurrence time.
We identified 26 studies, with a total of 5100 patients and 321 with recurrences (pooled rate, 6.2%). The risk of recurrence was significantly higher in positive vertical margin (RR, 4.51; 95% confidence interval [CI], 2.16-9.44), positive horizontal margin (RR, 2.54; 95% CI, 1.57-4.13), lymphovascular invasion (LVI) (RR, 2.33; 95% CI, 1.75-3.11; P < .001), lymphatic invasion (LI) (RR, 2.24; 95% CI, 1.24-4.06), and tumor invading submucosa of ≤200 μm (SM1) (RR, 1.71; 95% CI, 1.32-2.21, compared to muscularis mucosa). Patients with LI (hazard ratio, 2.47; 95% CI, 1.24-4.90; P = .02) and LVI (HR, 2.36; 95% CI, 2.22-4.59; P = .0006) tended to have earlier recurrence after ER.
The recurrence rate of superficial esophageal squamous cell carcinoma after ER is acceptable. Patients with positive margins, LVI, LI, and SM1 need to pay significant attention to the risk of recurrence. LI and VI should be evaluated separately. (PROSPERO CRD42023406309.).
关于浅表性食管鳞状细胞癌(ESCC)内镜切除(ER)术后复发的风险及病理因素,各研究结果并不一致。我们通过一项系统评价和荟萃分析对此进行评估。
从所有研究中提取此类患者的复发数据。采用随机效应荟萃分析合并风险比(RRs),以评估汇总复发率及病理风险因素。采用Kaplan-Meier方法合并无复发生存率,以估计各种病理因素与复发时间之间的关系。
我们纳入了26项研究,共5100例患者,其中321例复发(汇总率为6.2%)。垂直切缘阳性(RR,4.51;95%置信区间[CI],2.16 - 9.44)、水平切缘阳性(RR,2.54;95% CI,1.57 - 4.13)、脉管侵犯(LVI)(RR,2.33;95% CI,1.75 - 3.11;P <.001)、淋巴管侵犯(LI)(RR,2.24;95% CI,1.24 - 4.06)以及肿瘤侵犯黏膜下层≤200μm(SM1)(与黏膜肌层相比,RR,1.71;95% CI,1.32 - 2.21)的患者复发风险显著更高。LI(风险比,2.47;95% CI,1.24 - 4.90;P = 0.02)和LVI(HR,2.36;95% CI,2.22 - 4.59;P = 0.0006)的患者ER术后复发往往更早。
ER术后浅表性食管鳞状细胞癌的复发率是可接受的。切缘阳性、LVI、LI和SM1的患者需要高度关注复发风险。LI和LVI应分别进行评估。(国际前瞻性系统评价注册库编号:CRD42023406309。)